Oculis (Nasdaq: OCS), a pioneering global biopharmaceutical company dedicated to revolutionizing eye care, has successfully raised an impressive $144 million in its latest funding round. This significant capital infusion is poised to accelerate the company鈥檚 mission of saving sight and addressing critical eye diseases with high unmet medical needs. Oculis boasts a robust clinical-stage pipeline featuring innovative product candidates, including OCS-01 eye drops, currently in Phase 3 development targeting diabetic macular edema (DME) and managing inflammation and pain after ocular surgery. Additionally, OCS-02 eye drops are making strides in Phase 2 trials for dry eye disease and uveitis, while OCS-05 represents a groundbreaking approach to treating acute optic neuritis and other neuro-ophthalmic disorders. This funding will enable Oculis to enhance its research capabilities, advance ongoing clinical trials, and broaden its product portfolio to meet the demands of patients worldwide. The company鈥檚 strategic operations across Switzerland, the US, Europe, and China reflect its commitment to delivering life-changing treatments globally. Led by a seasoned management team with a proven track record in the pharmaceutical industry, supported by esteemed international healthcare investors, Oculis is on a path to redefine eye care and make significant impacts on patient outcomes. As the company continues its journey toward innovation in ophthalmology, this funding milestone marks a pivotal step toward achieving its vision of comprehensive solutions for various eye diseases.
Oculis Raises $144 Million to Advance Life-Changing Eye Treatments Worldwide
Recently funded 路 $144.0MBiopharmaceutical
Get the full Oculis company profile
Access contacts, investors, buying signals & more
Other recently funded companies
View all
Laihua Online
Wuhan Laihua Information and Technology is an Internet leading source of information on educational opportunities for students to study in other countries especially in China. Either prospect is planning to come to China or is already in China for education (self-support or scholarship based) he will probably need one of the ranges of services we provide from Education, Translation, Notarization of legal documents to Internships & Jobs or Medical Tourism etc. It is a comprehensive directory of study abroad programs, including summer study abroad, service learning, intensive language programs and more. Wuhan Laihua Information and Technology first set out to fill the information gap between students with a desire to travel abroad to study and companies offering international programs.
$68.0M Series d
today
NEW ID
NEW ID is the latest subsidiary company of NEW, which has started up since August 2019 for a new digital contents/platform business domain. We are responsible for expanding the contents produced and acquired by NEW into various markets and creating our digital capabilities through partnering with a-lister digital content creators and providers in Korea.
